Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Interleukin-2 for Steroid-Dependent Nephrotic Syndrome in Children
NCT02997150Phase 2Withdrawn
- Sponsor
- CHU de Limoges
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of aldesleukin in Idiopathic nephrotic syndrome (INS), sponsored by CHU de Limoges. Planned start Feb 2017; status: withdrawn.
02
Drugs
aldesleukin
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT02997150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997150.